Sappiens
A biotech developing a drug candidate in Parkinson's disease and ALS
2026
Gabrielle Gache
Licensing specialist, President of the Swiss Healthcare Licensing Group, based at the Biopôle in Lausanne.
Why Valeureux invested
Potentially the first neuroprotective treatment in Parkinson's disease. An open pipeline that includes ALS.